Effects of Sorafenib on Symptoms and Quality of Life

Murphy, 1995, American Cancer Society Textbook of Clinical Oncology, 2nd ed., 635

Victorson, 2006, Meta analysis of the correlation between radiographic tumor response and patient-reported outcomes., Cancer, 106, 494, 10.1002/cncr.21637

Glaspy, 2002, Therapeutic options in the management of renal cell carcinoma., Semin Oncol, 29, 41, 10.1053/sonc.2002.33083

Motzer, 2004, Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma., J Clin Oncol, 22, 454, 10.1200/JCO.2004.06.132

Fish, 1999, Quality of life issues in the management of ovarian cancer., Semin Oncol, 26, 32

Szende, 2005, Health-related quality of life and other patient-reported outcomes in the European centralized drug regulatory process: a review of guidance documents and performed authorizations of medicinal products 1995 to 2003., Value Health, 8, 534, 10.1111/j.1524-4733.2005.00051.x

Cella, 2006, Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)., J Support Oncol, 4, 191

Eisen, 2006, Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival., J Clin Oncol, 24, 4524, 10.1200/jco.2006.24.18_suppl.4524

Escudier, 2005, Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)., J Clin Oncol, 23, 4510, 10.1200/jco.2005.23.16_suppl.lba4510

Cella, 2005, FACIT Manual: Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, Version 4.

Webster, 2003, The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation., Health Qual Life Outcomes, 1, 79, 10.1186/1477-7525-1-79

Sutherland, 1990, Ratings of the importance of quality of life variables: therapeutic implications for patients with metastatic breast cancer., J Clin Epidemiol, 43, 661, 10.1016/0895-4356(90)90036-O

Chawla, 2005, Impact of bevacizumab plus 5-FU/LV with or without irinotecan on quality of life in patients with metastatic colorectal cancer.

Escudier, 2007, Sorafenib for advanced clear-cell renal cell carcinoma. Global Evaluation Trial (TARGETs): a randomized, double-blind, placebo-controlled phase III trial of sorafenib, an oral multi-kinase inhibitor in advanced renal cell carcinoma., N Engl J Med, 356, 185